Sun Pharma is considering expanding its manufacturing operations in the United States as the Trump administration enforces a 100% tariff on branded and patented medicines. The company’s North America leadership noted during an analyst interaction that Sun Pharma already operates facilities in the US and regularly reviews opportunities to strengthen or localise production. The evolving tariff environment, however, remains unpredictable, making it difficult to assess its potential impact on the company’s generics and innovative product portfolios.
Executive Chairman Dilip Shanghvi informed analysts that the company is preparing to launch UNLOXCYT, its FDA-approved therapy for advanced skin cancer, in the US in the second half of FY26. Sun Pharma also plans to file a supplemental biologics application for ILUMYA in psoriatic arthritis within the same period.
Despite trade uncertainties, the company continues to invest heavily in research and development to advance its specialty and innovative medicines pipeline.
Also Read